As health care systems grow increasingly complex, pharmacists are key members of the patient care team. This webinar, in collaboration with the World Patients Alliance, will explore how pharmacists contribute to safer care through medication management, patient empowerment, and interprofessional collaboration. It will also highlight the patient perspective by showing how patients and families contribute to safer medication use through shared decision-making, early reporting of concerns, health literacy, and partnerships with pharmacists and other health professionals. Pharmacists’ expertise in disease prevention and patient-centred care is increasingly vital, highlighting the importance of teamwork and shared decision-making in achieving safer and more effective treatment outcomes for the patients.

In collaboration with: World Patients Alliance

Co-Chairs:
- Marianne Ivey, Professor, Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy, the University of Cincinnati, USA
- Helen Haskell, Chair of WPA Patient Safety & Quality Council, World Patients Alliance (WPA), USA

Panellists:
- John Hertig, Adjunct Assistant Professor, Purdue University; Founder and President, Hertig Healthcare Advising LLC, USA
- Regina Mariam Namata Kamoga, Executive Director, Community Health and Information Network (CHAIN), Uganda
- Mohamed Elsabakhawi, Pharmacist/Owner, Shoppers Drug Mart, Canada

*Please note that a Zoom account is required to register for this FIP Digital Event. If you are receiving an error message during registration, please create a Zoom account and use the corresponding email address for your registration.

Poorly water-soluble drugs remain a major challenge in oral drug development. Amorphous solid dispersions (ASDs) and lipid-based formulations (LBFs) are the two most widely used enabling technologies, each improving bioavailability by generating and maintaining intestinal supersaturation. Although they use different formulation approaches, both aim to keep drugs in a non-crystalline, molecularly dispersed state and rely on amorphous drug-rich nanodroplets to support absorption. Increasingly, ASD and LBF strategies are converging through the incorporation of surfactants, polymers, and hybrid technologies. Formulation selection depends on physicochemical properties, manufacturing considerations, and development needs. Emerging beyond-rule-of-5 molecules will require advanced hybrid approaches addressing both solubility and permeability limitations.

Moderator:

- Dr. Mathew Cherian PhD, VP of Operations and R&D, ReVive Biotechnology, USA
- Ms Qurrotul Aini Shodiquna, IPS Liaison at FIP ECPG, Indonesia

Panellist:

- Dr. Jaspreet Arora PhD, Associate Director, CMC, BridgeBio Oncology Therapeutics, USA

**Please register using the email address associated with your Zoom account. If you do not have a Zoom account, please create one and use the corresponding email address in the registration form.

**Registrants do not need to be FIP members to sign up for the webinar.

The Journal of Pharmaceutical Policy and Practice (JoPPP) was established in 2008 with the mission to promote pharmaceutical policy and practice globally. The journal is published in the United Kingdom, indexed in Scopus and PubMed Central, and managed by a distinguished international editorial board. Based on its growing body of research articles, presentations, and best practices, JoPPP will hold the “5th JOPPP IMPACT MONGOLIA - 2026” conference in collaboration with Etugen University on November 11–13, 2026.

Join us for the world’s first LGBTQIA+-focused pharmacy conference, proudly endorsed by the International Pharmaceutical Federation (FIP). This landmark three-day event brings together LGBTQIA+ pharmacists, students, educators, researchers and allies to build a more inclusive and culturally safe future for pharmacy practice.